Key Takeaways:
- Gilead Sciences (GILD, Financial) is scheduled to release its Q1 earnings on April 24th.
- Analysts predict an EPS of $1.74 and revenue of $6.78 billion.
- Investors should watch the impact of tariffs, HIV prevention launch, and growth projections.
Upcoming Earnings Release
Gilead Sciences (GILD) is set to announce its first-quarter earnings on April 24th, post-market close. Analysts anticipate an earnings per share (EPS) of $1.74 alongside expected revenue of $6.78 billion. The key areas of focus will be the implications of current tariffs, the recent launch in HIV prevention, and the company's growth projections. Notably, recent trends have shown mixed revisions in both EPS and revenue forecasts.
Wall Street Analysts Forecast
When considering the one-year price targets set by 24 industry analysts, Gilead Sciences Inc (GILD, Financial) holds an average target price of $111.81. The high estimate reaches $140.00, while the low stands at $82.00. This average target suggests an upside of 5.83% from the current stock price of $105.65. For further insight, investors can visit the Gilead Sciences Inc (GILD) Forecast page.
The consensus recommendation from 30 brokerage firms positions Gilead Sciences Inc (GILD, Financial) at an average brokerage recommendation of 2.1, which aligns with an "Outperform" rating. This rating scale, ranging from 1 to 5, categorizes 1 as a Strong Buy and 5 as a Sell.
GuruFocus GF Value Estimate
According to GuruFocus estimates, the projected GF Value of Gilead Sciences Inc (GILD, Financial) in one year is $80.51. This suggests a potential downside of 23.8% from the current trading price of $105.65. GF Value is a key metric by GuruFocus, reflecting the fair value a stock should be traded at, based on historical trading multiples, past business growth, and future performance forecasts. For comprehensive data, please refer to the Gilead Sciences Inc (GILD) Summary page.
